Cancer immunotherapy targeting anti-PD-1 (e.g., nivolumab, pembrolizumab), as well as anti-cytotoxic T-lymphocyte-associated antigen 4 (anti-CTLA-4, ipilimumab), has changed the treatment landscape of several tumors (29). Here, CTLA4 is linked to cancer.